Empire Blue Cross

Billing Clarification for Bevacizumab
(J3490/J3590/J9035)

Empire Blue Cross (Empire) has received numerous providers submitting claims for Bevacizumab (also know commercially as Avastin) using the following codes improperly. Please see the approved Medicare Billing guidelines below.

- **J3490 or J3590** are approved and valid codes for Bevacizumab when treating neovascular age-related macular degeneration (AMD) by an Ophthalmologist. The administration CPT code for the administration of J3490 or J3590 is 67038.

- **J9035** is used for Bevacizumab, but **is not approved** for use when treating neovascular age-related macular degeneration (AMD) by an Ophthalmologist. These are higher dosage treatments approved only for the treatment of select cancers.

Empire recognizes the possibility of confusion when billing for Bevacizumab and has provided these guidelines to assist our providers in following CMS guidelines. However, continued improper use of J9035 after the provider has been educated may result in the denial of the claim and possible abuse investigations.

Y0017_14_20510_I_004
Empire Blue Cross and Blue Shield

Billing Clarification for Bevacizumab
(J3490/J3590/J9035)

Empire Blue Cross and Blue Shield (Empire) has received numerous providers submitting claims for Bevacizumab (also known commercially as Avastin) using the following codes improperly. Please see the approved Medicare Billing guidelines below.

- **J3490 or J3590** are approved and valid codes for Bevacizumab when treating neovascular age-related macular degeneration (AMD) by an Ophthalmologist. The administration CPT code for the administration of J3490 or J3590 is 67038.

- **J9035** is used for Bevacizumab, but is not approved for use when treating neovascular age-related macular degeneration (AMD) by an Ophthalmologist. These are higher dosage treatments approved only for the treatment of select cancers.

Empire recognizes the possibility of confusion when billing for Bevacizumab and has provided these guidelines to assist our providers in following CMS guidelines. However, continued improper use of J9035 after the provider has been educated may result in the denial of the claim and possible abuse investigations.